Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription Articles published in Gastroenterology Retrieve available abstracts of 112 articles: HTML format

Single Articles

October 2025
1. FOX D, Xie J, Burwinkel JL, Adams JM, et al
   Adeno-associated Virus-mediated Silencing of Sox4 Leads to Long-Term Amelioration of Liver Phenotypes in Mouse Models of Alagille Syndrome.
   Gastroenterology. 2025;169:1000-1016.
   PubMed     Abstract available
   
   
   September 2025
2. SINGAL AG, Salem R, Pinato DJ, Pillai A, et al
   Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma.
   Gastroenterology. 2025;169:585-599.
   PubMed     Abstract available
   
   
   
3. ROHM TV, Dos Reis FCG, Cunha E Rocha K, Isaac R, et al
   Adipose Tissue Macrophages in Metabolic Dysfunction-Associated Steatohepatitis Secrete Extracellular Vesicles That Activate Liver Fibrosis in Obese Male Mice.
   Gastroenterology. 2025;169:691-704.
   PubMed     Abstract available
   
   
   
4. JIANG C, Li Z, Seok S, Li P, et al
   Systemic Identification of Functionally Conserved Long Noncoding RNA Metabolic Regulators in Human and Mouse Livers.
   Gastroenterology. 2025;169:676-690.
   PubMed     Abstract available
   
   
   August 2025
5. LI L, Wang Y, Deng B
   A Patient with Liver Injury, Portal Hypertension, Anemia, and Peripheral Neuropathy.
   Gastroenterology. 2025 Aug 25:S0016-5085(25)05908.
   PubMed    
   
   
   
6. LOU TW, Ren TY, Fan JG
   An Unusual Cause of Hypolipidemia With Cirrhosis in a Father-Son Pair.
   Gastroenterology. 2025 Aug 21:S0016-5085(25)05901.
   PubMed    
   
   
   
7. LIU WY, Huang S, Ji H, Kim SU, et al
   From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic Perspective.
   Gastroenterology. 2025;169:326-336.
   PubMed     Abstract available
   
   
   
8. SPANN A, Strauss AT, Davis SE, Bhat M, et al
   The Role of Artificial Intelligence in Chronic Liver Diseases and Liver Transplantation.
   Gastroenterology. 2025;169:456-470.
   PubMed     Abstract available
   
   
   July 2025
9. RUSSI AE, DeBosch BJ
   Interdicting nuclear autophagy to treat metabolic dysfunction-associated steatohepatitis.
   Gastroenterology. 2025 Jul 29:S0016-5085(25)05794.
   PubMed    
   
   
   
10. SHI X
    Visualization Score Might be Considered for Hepatocellular Carcinoma Surveillance.
    Gastroenterology. 2025 Jul 23:S0016-5085(25)05788.
    PubMed    
    
    
    
11. FERNANDEZ-GARIBAY VM, Chavez-Tapia NC
    Thoughts on "Noncontrast magnetic resonance imaging vs ultrasonography for hepatocellular carcinoma surveillance".
    Gastroenterology. 2025 Jul 23:S0016-5085(25)05791.
    PubMed    
    
    
    
12. WANG Y, Huang Y, Zhang G, Wang S, et al
    Noncontrast MRI in Hepatocellular Carcinoma Surveillance: Considerations for Implementation in Clinical Practice.
    Gastroenterology. 2025 Jul 23:S0016-5085(25)05790.
    PubMed    
    
    
    
13. SILVEY S, Kamath PS, George J, Choudhury A, et al
    Enhancement of Inpatient Mortality Prognostication with Machine Learning in a Prospective Global Cohort of Patients with Cirrhosis with External Validation.
    Gastroenterology. 2025 Jul 18:S0016-5085(25)05770.
    PubMed     Abstract available
    
    
    
14. ACKERMANN O, Bernard O, Franchi-Abella S, Almes M, et al
    The natural history of gastroesophageal varices in children with portal hypertension.
    Gastroenterology. 2025 Jul 15:S0016-5085(25)05748.
    PubMed     Abstract available
    
    
    June 2025
15. JING S, Song J
    Comments on "Multi-HCC: A Practical Model to Prioritize Patients With Hepatocellular Carcinoma on the Liver Transplant Waiting List".
    Gastroenterology. 2025 Jun 10:S0016-5085(25)00884.
    PubMed    
    
    
    
16. BAJAJ JS, Shawcross DL, Choudhury A, Karvellas CJ, et al
    Defining Organ Failures in Patients with Cirrhosis: Consensus Statements.
    Gastroenterology. 2025 Jun 9:S0016-5085(25)00844.
    PubMed    
    
    
    
17. MCGETTIGAN B, Hernandez-Tejero M, Malhi H, Shah V, et al
    Immune Dysfunction and Infection Risk in Advanced Liver Disease.
    Gastroenterology. 2025;168:1085-1100.
    PubMed     Abstract available
    
    
    May 2025
18. JUANOLA A, Ma AT, Cullaro G, Alexander MP, et al
    DEVELOPMENT OF ACUTE KIDNEY INJURY IN A PATIENT WITH ALCOHOL-RELATED CIRRHOSIS: THE IMPORTANCE OF DIAGNOSING THE CAUSE OF AKI.
    Gastroenterology. 2025 May 19:S0016-5085(25)00764.
    PubMed    
    
    
    
19. XUE H, Wang L, Sun D, Wu Y, et al
    Associations of alcohol consumption and genetic predisposition to hepatic steatosis with liver-related events: results from large population-based cohort studies.
    Gastroenterology. 2025 May 14:S0016-5085(25)00712.
    PubMed     Abstract available
    
    
    
20. SHUNG DL, Iacucci M
    Artificial Intelligence in Gastroenterology and Hepatology: Potential and Perils.
    Gastroenterology. 2025 May 13:S0016-5085(25)00710.
    PubMed    
    
    
    April 2025
21. HUPPERTZ I, Mullen AC
    Function over form: defining evolutionarily conserved long-noncoding RNAs regulating hepatic metabolism.
    Gastroenterology. 2025 Apr 25:S0016-5085(25)00641.
    PubMed    
    
    
    
22. LENS S
    Simvastatin and Rifaximin for Decompensated Cirrhosis: A Hope Unfulfilled.
    Gastroenterology. 2025 Apr 23:S0016-5085(25)00638.
    PubMed    
    
    
    
23. YOUNOSSI ZM, Zelber-Sagi S, Lazarus JV, Wai-Sun Wong V, et al
    Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis.
    Gastroenterology. 2025 Apr 11:S0016-5085(25)00632.
    PubMed     Abstract available
    
    
    
24. GUPTA V, Sehrawat TS, Pinzani M, Strazzabosco M, et al
    Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities.
    Gastroenterology. 2025;168:675-690.
    PubMed     Abstract available
    
    
    March 2025
25. SILVEY S, Patel N, Khoruts A, Bajaj JS, et al
    Rifaximin does not increase the rate of 30-day mortality in patients with cirrhosis and daptomycin in two National US-based cohorts.
    Gastroenterology. 2025 Mar 21:S0016-5085(25)00535.
    PubMed    
    
    
    
26. KISSELEVA T, Ganguly S, Murad R, Wang A, et al
    Regulation of Hepatic Stellate Cell Phenotypes in MASH.
    Gastroenterology. 2025 Mar 20:S0016-5085(25)00528.
    PubMed     Abstract available
    
    
    February 2025
27. PAN S, Chen J, Li X
    An Unusual Case of Unexplained Portal Hypertension and Splenomegaly.
    Gastroenterology. 2025 Feb 18:S0016-5085(25)00374.
    PubMed    
    
    
    
28. PEERY AF, Murphy CC, Anderson C, Jensen ET, et al
    Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024.
    Gastroenterology. 2025 Feb 4:S0016-5085(25)00034.
    PubMed     Abstract available
    
    
    
29. FROMME M, Payance A, Mandorfer M, Thorhauge KH, et al
    Longitudinal Evaluation of Individuals With Severe Alpha-1 Antitrypsin Deficiency (Pi *ZZ Genotype).
    Gastroenterology. 2025;168:367-381.
    PubMed     Abstract available
    
    
    January 2025
30. KUMAR N, Chaudhary A
    Comments on "Recompensation of Chronic Hepatitis C-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program".
    Gastroenterology. 2025 Jan 30:S0016-5085(25)00326.
    PubMed    
    
    
    
31. KRONSTEN VT, Paintsil EK, Rodrigues S, Seager MJ, et al
    Hepatic encephalopathy - when lactulose and rifaximin are not working.
    Gastroenterology. 2025 Jan 24:S0016-5085(25)00050.
    PubMed    
    
    
    
32. RHEE H, Kim MJ, Kim DY, An C, et al
    Non-contrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance: A randomized, single-center trial.
    Gastroenterology. 2025 Jan 22:S0016-5085(25)00049.
    PubMed     Abstract available
    
    
    December 2024
33. DAVIS JPE, Lim JK, Francis FF, Ahn J, et al
    AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review.
    Gastroenterology. 2024 Dec 20:S0016-5085(24)05664.
    PubMed     Abstract available
    
    
    November 2024
34. NORMAN J, Mehta N, Kim WR, Liang JW, et al
    Multi-HCC: A practical model to prioritize patients with hepatocellular carcinoma on the liver transplant waiting list.
    Gastroenterology. 2024 Nov 30:S0016-5085(24)05754.
    PubMed     Abstract available
    
    
    
35. MEZZACAPPA C
    Gastro Digest: The Revised REACH-B Model Predicts Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.
    Gastroenterology. 2024 Nov 30:S0016-5085(24)05756.
    PubMed    
    
    
    
36. MULLISH BH
    New agonists of the incretin/glucagon system for the treatment of metabolic dysfunction-associated steatohepatitis.
    Gastroenterology. 2024 Nov 30:S0016-5085(24)05755.
    PubMed    
    
    
    
37. FOERSTER F, Galle PR
    To Look or Not to Look: A New Score for Stratifying Patients at Risk of Developing Hepatocellular Carcinoma.
    Gastroenterology. 2024 Nov 30:S0016-5085(24)05753.
    PubMed    
    
    
    
38. ELLER M, Westbrook L, Kalra A
    Expanding the Differential Diagnosis: Severe, Swollen Hepatocytes in a Patient with an ALT above 1000 U/L.
    Gastroenterology. 2024 Nov 16:S0016-5085(24)05697.
    PubMed    
    
    
    
39. FUJIWARA N, Lopez C, Marsh TL, Raman I, et al
    Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis.
    Gastroenterology. 2024 Nov 7:S0016-5085(24)05660.
    PubMed     Abstract available
    
    
    
40. DE ALMEIDA SOUZA GL, Chebli VA, Fonseca Chebli JM
    An intriguing case of hepatosplenic lesions and pneumonia during anti-TNF therapy for IBD.
    Gastroenterology. 2024 Nov 6:S0016-5085(24)05661.
    PubMed    
    
    
    
41. DORNER H, Stolzer I, Mattner J, Kaminski S, et al
    Gut Pathobiont-Derived Outer Membrane Vesicles Drive Liver Inflammation and Fibrosis in Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease.
    Gastroenterology. 2024;167:1183-1197.
    PubMed     Abstract available
    
    
    October 2024
42. WANG Z, Li J, Li Y
    Insights into the protective role of GLP-1RAs in the treatment of type 2 diabetes mellitus: implications for hepatocellular carcinoma and hepatic dysfunction.
    Gastroenterology. 2024 Oct 17:S0016-5085(24)05578.
    PubMed    
    
    
    
43. WEI JC, Wu CN, Cheng WC
    Comments on "Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes".
    Gastroenterology. 2024 Oct 17:S0016-5085(24)05581.
    PubMed    
    
    
    
44. WEI JC, Kuo P, Mei Q
    Methodology of Study on GLP-1 Receptor Agonists and Hepatocellular Carcinoma Risk.
    Gastroenterology. 2024 Oct 17:S0016-5085(24)05579.
    PubMed    
    
    
    
45. LIU Z, Shan D, Han X
    GLP-1 Receptor Agonists' Role in Reducing Hepatocellular Carcinoma Risk.
    Gastroenterology. 2024 Oct 16:S0016-5085(24)05580.
    PubMed    
    
    
    
46. RATHORE M, Curry K, Huang W, Wright M, et al
    LRG1 promotes metastatic colorectal cancer growth through HER3 signaling.
    Gastroenterology. 2024 Oct 9:S0016-5085(24)05566.
    PubMed     Abstract available
    
    
    
47. KOTHARI S, Afshar Y, Friedman LS, Ahn J, et al
    AGA Clinical Practice Update on Pregnancy-Related Gastrointestinal and Liver Disease: Expert Review.
    Gastroenterology. 2024;167:1033-1045.
    PubMed     Abstract available
    
    
    
48. HUPERTZ VF
    A Further Step Toward Possible Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.
    Gastroenterology. 2024;167:847-848.
    PubMed    
    
    
    
49. CLARK VC, Strange C, Strnad P, Sanchez AJ, et al
    Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA).
    Gastroenterology. 2024;167:1008-1018.
    PubMed     Abstract available
    
    
    
50. ALLEGRETTI JR, Khanna S, Mullish BH, Feuerstadt P, et al
    The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond.
    Gastroenterology. 2024;167:885-902.
    PubMed     Abstract available
    
    
    September 2024
51. MAK LY, Yuen MF
    Surveillance for hepatocellular carcinoma in cirrhosis: End of monopoly for serum alpha fetoprotein.
    Gastroenterology. 2024 Sep 28:S0016-5085(24)05533.
    PubMed    
    
    
    
52. MARSH TL, Parikh ND, Roberts LR, Schwartz ME, et al
    A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis.
    Gastroenterology. 2024 Sep 16:S0016-5085(24)05460.
    PubMed     Abstract available
    
    
    
53. GINES P, Serra-Burriel M
    Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Steatotic Liver Disease in Patients With Type 2 Diabetes Mellitus: Growing Evidence But Not Yet There.
    Gastroenterology. 2024;167:653-655.
    PubMed    
    
    
    
54. ASOMBANG AW, Mohamed MF, Egboh SC, Omede M, et al
    The Importance of Global Health Training in US-Based Gastroenterology and Hepatology Fellowship Programs.
    Gastroenterology. 2024;167:643-648.
    PubMed    
    
    
    August 2024
55. PREMKUMAR M, Dhiman RK, Duseja A, Mehtani R, et al
    Recompensation of Chronic Hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: Prospective Cohort study from an HCV elimination program.
    Gastroenterology. 2024 Aug 22:S0016-5085(24)05359.
    PubMed     Abstract available
    
    
    
56. GIBBENS Y, Lake J, Lim N
    A Rare Cause of Acute Liver Failure.
    Gastroenterology. 2024;167:446-449.
    PubMed    
    
    
    
57. CHENG X, Dai E, Wu J, Flores NM, et al
    Atlas of metastatic gastric cancer links ferroptosis to disease progression and immunotherapy response.
    Gastroenterology. 2024 Aug 1:S0016-5085(24)05297.
    PubMed     Abstract available
    
    
    July 2024
58. VAN KLEEF LA, Francque SM, Prieto-Ortiz JE, Sonneveld MJ, et al
    Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction.
    Gastroenterology. 2024;167:357-367.
    PubMed     Abstract available
    
    
    
59. NAIMIMOHASSES S, Bhat M
    Novel Multimodal Database for Metabolic Dysfunction-Associated Steatotic Liver Disease-Linking Genes to Outcomes.
    Gastroenterology. 2024;167:410-411.
    PubMed    
    
    
    
60. SUI B, Wang R, Chen C, Kou X, et al
    Apoptotic Vesicular Metabolism Contributes to Organelle Assembly and Safeguards Liver Homeostasis and Regeneration.
    Gastroenterology. 2024;167:343-356.
    PubMed     Abstract available
    
    
    June 2024
61. ZENG T, Xiong J, Li X
    A rare cause of hepatic mass with high metabolic activity and jaundice.
    Gastroenterology. 2024 Jun 29:S0016-5085(24)05173.
    PubMed    
    
    
    
62. SUTTON H, Bhat M
    Novel migratory hepatocyte population contributes to liver regeneration in acute liver injury.
    Gastroenterology. 2024 Jun 27:S0016-5085(24)05176.
    PubMed    
    
    
    
63. KO S, Monga SP
    The dark side of human hepatocyte plasticity.
    Gastroenterology. 2024 Jun 25:S0016-5085(24)05116.
    PubMed    
    
    
    
64. LENS S
    Resmetirom for Non-alcoholic Steatohepatitis.
    Gastroenterology. 2024 Jun 25:S0016-5085(24)05120.
    PubMed    
    
    
    
65. VENKATESWARAN N
    Seladelpar as an alternate second line agent for Primary Biliary Cirrhosis.
    Gastroenterology. 2024 Jun 20:S0016-5085(24)05064.
    PubMed    
    
    
    
66. ZHU CP, Liu SQ, Wang KQ, Xiong HL, et al
    Targeting 5-Hydroxytryptamine receptor 1A in portal vein to decrease portal hypertension.
    Gastroenterology. 2024 Jun 19:S0016-5085(24)05062.
    PubMed     Abstract available
    
    
    
67. HSU BY, Driscoll J, Tateno C, Mattis AN, et al
    Human Hepatocytes Can Give Rise To Intrahepatic Cholangiocarcinomas.
    Gastroenterology. 2024 Jun 10:S0016-5085(24)05028.
    PubMed    
    
    
    
68. LEE BP, Louvet A
    Longitudinal Change of Alcohol Use is a Dynamic Contributor to Steatotic Liver Disease Progression.
    Gastroenterology. 2024;166:965-967.
    PubMed    
    
    
    
69. LO GH
    The Optimal Duration of Vasoconstrictors for Acute Variceal Hemorrhage: Longer Is Safer?
    Gastroenterology. 2024;166:1197-1198.
    PubMed    
    
    
    
70. WANG H, Yuan S, Zheng Q, Zhang S, et al
    Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.
    Gastroenterology. 2024;166:1130-1144.
    PubMed     Abstract available
    
    
    May 2024
71. HANSCOM M
    Magnetically guided capsule endoscopy comparable to EGD for detecting esophagogastric varices in patients with cirrhosis.
    Gastroenterology. 2024 May 28:S0016-5085(24)05001.
    PubMed    
    
    
    
72. WANG R, Li B, Huang B, Li Y, et al
    Gut microbiota-derived butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis.
    Gastroenterology. 2024 May 27:S0016-5085(24)04936.
    PubMed     Abstract available
    
    
    
73. HILSCHER MB, Wysokinski WE, Andrews JC, Simonetto DA, et al
    Portal Vein Thrombosis in the Setting of Cirrhosis: Evaluation and Management Strategies.
    Gastroenterology. 2024 May 25:S0016-5085(24)04951.
    PubMed    
    
    
    
74. CHANG M, Hammami MB, Sakiani S
    A Case of Hepatobiliary Challenges: Unraveling the Mystery of Bile Duct Disappearance.
    Gastroenterology. 2024 May 14:S0016-5085(24)04914.
    PubMed    
    
    
    
75. NIEMI NM, Debosch BJ
    Survival of the Fittest: Clonal Selection of Somatic Mutations Reveals Targets to Abate Chronic Liver Injury.
    Gastroenterology. 2024;166:936-937.
    PubMed    
    
    
    
76. GEORGE B, Kudryashova O, Kravets A, Thalji S, et al
    Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    Gastroenterology. 2024;166:859-871.
    PubMed     Abstract available
    
    
    
77. SCHONAUER R, Sierks D, Boerrigter M, Jawaid T, et al
    Sex, Genotype, and Liver Volume Progression as Risk of Hospitalization Determinants in Autosomal Dominant Polycystic Liver Disease.
    Gastroenterology. 2024;166:902-914.
    PubMed     Abstract available
    
    
    April 2024
78. WANG L, Berger NA, Kaelber DC, Xu R, et al
    Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes.
    Gastroenterology. 2024 Apr 29:S0016-5085(24)00494.
    PubMed     Abstract available
    
    
    
79. JIANG C, Lian M, Ma X
    A Rare Case Mimicking Congenital Hepatic Fibrosis.
    Gastroenterology. 2024 Apr 23:S0016-5085(24)00483.
    PubMed    
    
    
    March 2024
80. CAMPANI C, Guido M, Marra F
    Elusive hepatic nodules.
    Gastroenterology. 2024 Mar 23:S0016-5085(24)00355.
    PubMed    
    
    
    
81. HOLTZ LR, DeBosch BJ
    Deploying Lactulose as a Prebiotic to Reduce Complications of Chronic Liver Disease.
    Gastroenterology. 2024;166:534-535.
    PubMed    
    
    
    
82. URIAS E, Tedesco NR, Oliveri A, Raut C, et al
    PNPLA3 Risk Allele Association With ALT Response to Semaglutide Treatment.
    Gastroenterology. 2024;166:515-517.
    PubMed    
    
    
    
83. GAO F, Seto WK, Zheng MH
    Preventing Overdiagnosis of Nonalcoholic Fatty Liver Disease: Established Cutoff Values for Transient Elastography Are Needed.
    Gastroenterology. 2024;166:541-542.
    PubMed    
    
    
    
84. AN T, Liu L, Li X
    Factors Associated With the Influence of Liver Fibrosis Should Be Fully Considered.
    Gastroenterology. 2024;166:540-541.
    PubMed    
    
    
    February 2024
85. WONG RJ, Yang Z, Cheung R, Singal AK, et al
    Impact of Longitudinal Alcohol Use Patterns on Long-Term Risk of Cirrhosis Among U.S. Veterans with Steatotic Liver Disease.
    Gastroenterology. 2024 Feb 28:S0016-5085(24)00238.
    PubMed     Abstract available
    
    
    
86. CHEN J, Feng W, Sun M, Huang W, et al
    TGF-beta1 Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis through Transcriptionally Upregulating PD-L1 and CXCL12.
    Gastroenterology. 2024 Feb 26:S0016-5085(24)00187.
    PubMed     Abstract available
    
    
    
87. LENS S
    In Search of the Best Second-Line Therapy for Primary Biliary Cholangitis.
    Gastroenterology. 2024 Feb 20:S0016-5085(24)00185.
    PubMed    
    
    
    
88. HERMS Q, Fuster-Anglada C, Juanola A
    Pembrolizumab-induced Liver Injury: Beyond Immune-Mediated Hepatitis.
    Gastroenterology. 2024 Feb 4:S0016-5085(24)00133.
    PubMed    
    
    
    
89. ALLEN AM, Pose E, Reddy KR, Russo MW, et al
    Nonalcoholic Fatty Liver Disease Gets Renamed as Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress But With Challenges.
    Gastroenterology. 2024;166:229-234.
    PubMed    
    
    
    
90. WALAYAT S, Pfau P
    2 AM in the Intensive Care Unit: What Could Go Wrong?
    Gastroenterology. 2024;166:e13-e15.
    PubMed    
    
    
    
91. BILAL M, Steinberg J, Louissaint J, Phan J, et al
    First Year on the Job as a Gastroenterologist and Hepatologist: Lessons Learned.
    Gastroenterology. 2024 Feb 1:S0016-5085(24)00125.
    PubMed    
    
    
    January 2024
92. POSE E, Piano S, Juanola A, Gines P, et al
    HEPATORENAL SYNDROME IN CIRRHOSIS.
    Gastroenterology. 2024 Jan 19:S0016-5085(24)00054.
    PubMed     Abstract available
    
    
    
93. LAURIDSEN MM, Gronkjaer LL, Khraibut S, Patel N, et al
    The multi-dimensional challenge of poor oral health in cirrhosis - disparities and solutions.
    Gastroenterology. 2024 Jan 13:S0016-5085(24)00043.
    PubMed    
    
    
    
94. MULLISH BH
    Risk Factors for Liver Cancer and Chronic Liver Disease-related Death: Are Sugar Substitutes Better Than the Real Thing?
    Gastroenterology. 2024;166:213-214.
    PubMed    
    
    
    
95. ZENG Q, Wu D, Tang H
    A Mysterious Abdominal Pain.
    Gastroenterology. 2024;166:27-30.
    PubMed    
    
    
    December 2023
96. MEZZACAPPA C, Bhat M
    Proteomic Panels for Alcohol-Associated Liver Disease: Accurate, but Different Enough From Existing Clinical Tests?
    Gastroenterology. 2023;165:1576.
    PubMed    
    
    
    November 2023
97. GARCIA-TSAO G, Abraldes JG, Rich NE, Wong VW, et al
    AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
    Gastroenterology. 2023 Nov 17:S0016-5085(23)05143.
    PubMed     Abstract available
    
    
    
98. KOJIMA H, Kadono K, Hirao H, Dery KJ, et al
    T Cell CEACAM1-TIM-3 Crosstalk Alleviates Liver Transplant Injury in Mice and Humans.
    Gastroenterology. 2023;165:1233-1248.
    PubMed     Abstract available
    
    
    
99. PENA-SANCHEZ JN, Osei JA, Teucher U, Tremblay M, et al
    Working With Indigenous Community and Patient Partners Is Essential to Advance Gastroenterology and Hepatology Research: Perspectives From Canada.
    Gastroenterology. 2023;165:1097-1101.
    PubMed    
    
    
    
100. LLOVET JM, Heikenwalder M
     Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology.
     Gastroenterology. 2023;165:1308-1310.
     PubMed    
     
     
     October 2023
101. AMPUERO J, Berzigotti A
     Prognostication in Advanced Chronic Liver Disease Using Liver Stiffness Measurement: Repetita Iuvant.
     Gastroenterology. 2023;165:829-831.
     PubMed    
     
     
     
102. SEMMLER G, Yang Z, Fritz L, Kock F, et al
     Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease.
     Gastroenterology. 2023;165:1041-1052.
     PubMed     Abstract available
     
     
     
103. MAN S, Deng Y, Ma Y, Fu J, et al
     Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China.
     Gastroenterology. 2023;165:1025-1040.
     PubMed     Abstract available
     
     
     
104. YIP TC, Fan JG, Wong VW
     China's Fatty Liver Crisis: A Looming Public Health Emergency.
     Gastroenterology. 2023;165:825-827.
     PubMed    
     
     
     
105. TICA S, Debosch BJ
     Bariatric Surgery for the Treatment of NASH-An Old Solution to a Newer Problem?
     Gastroenterology. 2023;165:1091.
     PubMed    
     
     
     
106. WATTACHERIL JJ, Abdelmalek MF, Lim JK, Sanyal AJ, et al
     AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
     Gastroenterology. 2023;165:1080-1088.
     PubMed     Abstract available
     
     
     September 2023
107. CHEN J, Yang Q, Wang C
     Multiple Hepatic Masses in a Patient with Crohn's disease.
     Gastroenterology. 2023 Sep 20:S0016-5085(23)05014.
     PubMed    
     
     
     
108. XIE L, Guo H
     Question on the use of BMI >/= 25 kg/m(2) to define obesity to analyze the incidence and risk factors of hepatic steatosis and hepatic fibrosis in the Chinese population.
     Gastroenterology. 2023 Sep 8:S0016-5085(23)04983.
     PubMed    
     
     
     
109. MEZZACAPPA C
     Survival in unresectable hepatocellular carcinoma treated with a new immune checkpoint and anti-angiogenic drug combination.
     Gastroenterology. 2023 Sep 6:S0016-5085(23)04976.
     PubMed    
     
     
     August 2023
110. SHEN C, Zhang J, Xia Q
     Unexpected Abdominal Wall Varices After Split-Liver Transplantation.
     Gastroenterology. 2023;165:354-356.
     PubMed    
     
     
     March 2023
111. GADIYARAM S, Nachiappan M, Kini D
     Liver SOL in a case of colon cancer, a red herring.
     Gastroenterology. 2023 Mar 24:S0016-5085(23)00534.
     PubMed    
     
     
     
112. KO PH, Tseng CW
     An Unusual Cause of Acute Cholecystitis.
     Gastroenterology. 2023 Mar 23:S0016-5085(23)00531.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.